BLANCA ESTELA BASTIDAS-RAMIREZ

Dr. BLANCA ESTELA BASTIDAS-RAMIREZ

Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2020 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
FIFabiola Solorzano Ibarra
Fabiola Solorzano Ibarra
AAAlan G Alejandre‐Gonzalez
Alan G Alejandre‐Gonzalez
PLPablo C Ortiz Lazareno
Pablo C Ortiz Lazareno
BBBLANCA ESTELA BASTIDAS-RAMIREZ
BLANCA ESTELA BASTIDAS-RAMIREZ
AZAbraham Zepeda‐Moreno
Abraham Zepeda‐Moreno
JHJesse Haramati
Jesse Haramati

1 January 2006 in Annals of Hepatology
Verified
Journal Article
Open access
PDF file
RTRodrigo Torres-Baranda
Rodrigo Torres-Baranda
BBBLANCA ESTELA BASTIDAS-RAMIREZ
BLANCA ESTELA BASTIDAS-RAMIREZ
MMMontserrat Maldonado-González
Montserrat Maldonado-González
LSLAURA V. SANCHEZ-OROZCO
LAURA V. SANCHEZ-OROZCO
EVEDUARDO VAZQUEZ VALLS
EDUARDO VAZQUEZ VALLS
APArturo Panduro
Arturo Panduro
Hepatitis B virus infection (HBV) with undetectable levels of HBsAg, has been named occult HBV infection and observed in immunosuppressed patients. The aim of this study was to determine the frequency of occult HBV infection in patients with HIV from the West of México, using a combination of serological markers and nPCR. Thirty eight HIV/AIDS patients, 32 men (84.2%) and 6 (5.8%) women, without liver damage related symptoms were studied. HBV coinfection was observed in 10 (26.3%) patients; while only 3 (7.9%) of them were positive to HBsAg. Thus, 7 (18.4%) occult HBV infected patients could be assessed in this population. One (10%) patient with occult HBV infection was positive to anti-HBs, in spite of the reinfection protection attributed to this serological marker. Anti-HBc was detected only in 2 (20%) patients with occult HBV infection. No significant association could be established between occult HBV infection and CD+4 cell count, biochemical, clinical parameters, AIDS stage, or any other risk factor. This study suggest that determination of HBV DNA utilizing highly sensitive techniques, as nPCR, should be performed to detect occult HBV infection, even in the absence of anti-HBc in HIV/ AIDS patients, in order to have a reliable diagnosis, prevent HBV dissemination and acute exacerbation of chronic hepatitis B or even fulminant hepatitis. To our knowledge this is the first study of occult HBV infection in Mexican patients with HIV. However, further studies are necessary in order to determine HBV genotypes and its relationship with evolution and clinical manifestation of the disease.

Verified
Journal Article
Open access
PDF file
Esteban Andrés Sánchez-JaramilloEsteban Andrés Sánchez-Jaramillo
Esteban Andrés Sánchez-Jaramillo
Luz Elena Gasca-LozanoLuz Elena Gasca-Lozano
Luz Elena Gasca-Lozano
JVJosé María Vera-Cruz
José María Vera-Cruz
LOLuis Daniel Hernández Ortega
Luis Daniel Hernández Ortega
CGCarmen Magdalena Gurrola-Díaz
Carmen Magdalena Gurrola-Díaz
ASAdriana Salazar-Montes
Adriana Salazar-Montes
Renal fibrosis is the final stage of chronic kidney injury characterized by glomerulosclerosis and tubulointerstitial fibrosis with parenchymal destruction. Quercetin belongs to the most studied flavonoids with antioxidant, anti-inflammatory, antifibrogenic, and antitumor activity. It modifies the TGF-β/Smad signaling pathway, decreasing profibrogenic expression molecules and inducing the expression of antioxidant, anti-inflammatory, and antifibrogenic molecules. However, quercetin exhibits poor water solubility and low absorption and bioavailability. This limitation was solved by developing a nanoparticles formulation that improves the solubility and bioavailability of several bioactive compounds. Therefore, we aimed to investigate the in vivo antifibrogenic effect of a quercetin nanoparticles formulation. Male C57BL/6 mice were induced into chronic renal failure with 50 mg/kg of adenine for four weeks. The animals were randomly grouped and treated with 25, 50, or 100 mg/kg of quercetin, either macroparticles or nanoparticles formulation. We performed biochemical, histological, and molecular analyses to evaluate and compare the effect of macroparticles versus nanoparticles formulation on kidney damage. Here, we demonstrated that smaller doses of nanoparticles exhibited the same beneficial effect as larger doses of macroparticles on preventing kidney damage. This finding translates into less quercetin consumption reaching the desired therapeutic effect.

27 December 2022 in Immunology
Verified
Journal Article
Closed access
GGGloria Yareli Gutierrez‐Silerio
Gloria Yareli Gutierrez‐Silerio
MBMiriam Ruth Bueno
Miriam Ruth Bueno
Natali Vega-MagañaNatali Vega-Magaña
Natali Vega-Magaña
BBBLANCA ESTELA BASTIDAS-RAMIREZ
BLANCA ESTELA BASTIDAS-RAMIREZ
JGJorge Gutierrez‐Franco
Jorge Gutierrez‐Franco
STSusana del Toro-Arreola
Susana del Toro-Arreola

6 August 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AGAngélica Sofía González-Garibay
Angélica Sofía González-Garibay
GSGeorgina Sandoval
Georgina Sandoval
OTOmar Torres
Omar Torres
BBBLANCA ESTELA BASTIDAS-RAMIREZ
BLANCA ESTELA BASTIDAS-RAMIREZ
ISIván Moises Sánchez-Hernández
Iván Moises Sánchez-Hernández
EPEduardo Padilla-Camberos
Eduardo Padilla-Camberos
Metabolic syndrome (MetS) comprises a cluster of metabolic risk factors, which include obesity, hypertriglyceridemia, high blood pressure, and insulin resistance. The purpose of this study was to evaluate the effects of laurate-bioconjugated fructans on pro- and anti-inflammatory cytokines in Wistar rats with MetS induced by a high-fat diet. Laurate-bioconjugated fructans were synthesized with agave fructans, immobilized lipase B, and vinyl laureate as the acylant. Groups were fed a standard diet (NORMAL), a high-fat diet (HFD), or a high-fat diet plus laurate-bioconjugated fructans (FL PREV) for 9 weeks. A fourth group received a high-fat diet for 6 weeks, followed by simultaneous exposure to a high-fat diet and laurate-bioconjugated fructans for 3 additional weeks (FL REV). The dose of laurate-bioconjugated fructans was 130 mg/kg. Laurate-bioconjugated fructans reduced food and energy intake, body weight, body mass index, abdominal circumference, adipose tissue, adipocyte area, serum triglycerides, insulin, insulin resistance, and C-reactive protein but they increased IL-10 protein serum levels and mRNA expression. The impact of laurate-bioconjugated fructans on zoometric and metabolic parameters supports their potential as therapeutic agents to improve obesity, obesity comorbidities, insulin resistance, type 2 diabetes mellitus, and MetS.

22 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
Jesús García-BañuelosJesús García-Bañuelos
Jesús García-Bañuelos
EOEden Oceguera-Contreras
Eden Oceguera-Contreras
ASAna Sandoval-Rodriguez
Ana Sandoval-Rodriguez
BBBLANCA ESTELA BASTIDAS-RAMIREZ
BLANCA ESTELA BASTIDAS-RAMIREZ
SLSilvia Lucano-Landeros
Silvia Lucano-Landeros
JAJuan Armendariz-Borunda
Juan Armendariz-Borunda
The development of several vaccines against the SARS-CoV2 virus and their application in millions of people have shown efficacy and safety in the transfer of genes to muscle turning this tissue into a protein-producing factory. Established advanced liver fibrosis, is characterized by replacement of hepatic parenchyma by tissue scar, mostly collagen type I, with increased profibrogenic and proinflammatory molecules gene expression. Matrix metalloproteinase 8 (MMP-8) is an interstitial collagen-degrading proenzyme acting preferentially on collagen type I when activated. This study was carried out to elucidate the effect of an intramuscularly delivered adenoviral vector containing proMMP-8 gene cDNA (AdhMMP8) in male Wistar rats with experimental advanced liver fibrosis induced by thioacetamide. Therapeutic effects were monitored after 1, 2, or 3 weeks of a single dose (3 × 1011 vp/kg) of AdhMMP8. Circulating and liver concentration of MMP-8 protein remained constant; hepatic fibrosis decreased up to 48%; proinflammatory and profibrogenic genes expression diminished: TNF-α 2.28-fold, IL-1 1.95-fold, Col 1A1 4-fold, TGF-β1 3-fold and CTGF 2-fold; and antifibrogenic genes expression raised, MMP-9 2.8-fold and MMP-1 10-fold. Our data proposes that the administration of AdhMMP8 in muscle is safe and effective in achieving liver fibrosis regression at a comparable extent as when the adenoviral vector is delivered systemically to reach the liver, using a minimally invasive procedure.